Frequently Asked Questions
The course is key to the mission of the International Society for Cardiovascular Translational Research (ISCTR), which is to shorten the time from discovery of a product until its approval for routine patient care. We believe that simultaneous consideration of the overall steps from scientific discovery to treatment will expedite the process. As a result, we developed this four-course certificate program in which all stakeholders — the FDA, medical device companies, pharmaceutical industries and health care payers — are represented.
The University of Arizona Office of Continuing and Professional Education is offering this fully asynchronous curriculum as an online program.
An international team of world-renowned presenters from academia, industry, the FDA, health care payers and clinical guidelines. Each is a leader in one aspect of the process of developing, testing or marketing cardiovascular research.
The course is offered online with three pathways — Devices, Drugs and Biologics. All participants must complete the 25 introductory lectures, which discuss animal models, applied statistics, regulatory requirements, 3D-printing, genetics, biomarkers, myocardial invasive and non-invasive imaging, intellectual property, clinical guidelines and the general principals of reimbursement. The present course consists of the Introductory lectures, the Device Pathway, to be followed by the Drugs and Biologic Pathways.
Cardiovascular Translational Research is the textbook, with each chapter written by one of the speakers from ISCTR’s annual scientific meetings.
All participants must take the Introductory module, then may choose which pathway to pursue: Devices, Drugs or Biologics. They may pursue all three pathways or just one. The first to be offered is the Medical Device Pathway.
Each module costs $3,000 to register. So, if a participant chooses to pursue all three pathways, their total cost is $12,000.
Participants who complete each module will receive a certificate of completion.